How to access Gocovri from Qatar, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Qatari patient with Parkinson's disease experiencing levodopa-induced dyskinesia, or OFF-episodes in the context of dyskinesia, may receive a prescription for Gocovri (amantadine extended-release) from their treating neurologist. Gocovri is FDA-approved for this indication and developed by Adamas Pharmaceuticals (acquired by Supernus). It is not a controlled substance. In Qatar, Gocovri is not routinely registered for outpatient dispensing, and access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Gocovri is an extended-release formulation of amantadine designed for once-daily bedtime dosing to deliver peak concentrations during daytime motor-activity hours. It is titrated from 137 mg to 274 mg over one week. Amantadine's NMDA receptor antagonism and dopaminergic effects reduce dyskinesia severity. Eligibility anchors to established Parkinson's disease, levodopa-induced dyskinesia documentation, and baseline renal function assessment (amantadine is renally cleared; dose adjustment required in renal impairment).
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Gocovri legally importable into Qatar?
Yes, through the Qatar Ministry of Health (MOH) named-patient / special-access import framework. The mechanism permits a Qatar-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable (immediate-release amantadine is distinct from Gocovri's ER bedtime-dosing profile), (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating neurologist. Parkinson's diagnosis, dyskinesia documentation (UDysRS or patient diary), and clinical rationale specifying ER formulation.
- Baseline assessment. Renal function (eGFR), orthostatic BP, hallucination/psychosis screening, sleep history.
- MOH named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Gocovri from authorised distribution under DSCSA.
- Ambient shipment. Gocovri ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle with titration instructions and bedtime-dosing guidance.
What documentation your physician needs
- Clinical rationale letter confirming Parkinson's dyskinesia and Gocovri as the indicated ER formulation
- Verification of Qatar medical license
- Dyskinesia scoring or patient diary evidence
- Baseline renal function (eGFR)
- Orthostatic BP, hallucination screen
- Planned titration schedule
Reserve Meds provides a physician documentation kit bundling templates MOH reviewers expect for Parkinson's dyskinesia named-patient imports.
Costs and timing
Gocovri's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 35,000-40,000 for continuous daily dosing. International logistics, MOH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete MOH application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Mechanism, approval status, and treatment course
Gocovri (amantadine extended-release) is a N-methyl-D-aspartate (NMDA) receptor antagonist with indirect dopaminergic and anticholinergic activity, delivered through a proprietary extended-release pharmacokinetic profile designed for evening dosing with peak concentrations during daytime motor-activity hours. FDA approval: 2017. EMA: not approved as of 2026; access in Europe runs through national named-patient and compassionate-use frameworks where available. The labelled indication is the treatment of levodopa-induced dyskinesia in Parkinson's disease patients, and as adjunctive therapy to levodopa/carbidopa for OFF-episodes. Gocovri is supplied through the US specialty distribution channel only; Reserve Meds sources from a US-licensed authorised wholesaler under Drug Supply Chain Security Act (DSCSA) chain-of-custody and ships under the documentation framework MOPH-PDC reviewers expect.
Dosing. Oral 137 mg capsule at bedtime for one week, then increased to 274 mg at bedtime as tolerated. Renal dose adjustment required: eGFR 30-59 mL/min/1.73m2 cap at 137 mg; eGFR 15-29 every-other-day dosing; eGFR <15 not recommended. The Qatari treating physician documents the planned dose, the titration interval, and the response endpoint in the MOPH-PDC application package.
Tertiary referral landscape in Qatar
Gocovri cases in Qatar are most commonly initiated and followed at tertiary referral centres with subspecialty expertise in the indication. These include Hamad General Hospital, Sidra Medicine (paediatric), and Al Wakra Hospital. The treating physician of record (the Qatari-licensed neurologist, haematologist, or relevant subspecialist) holds clinical responsibility for the case; Reserve Meds does not interpose between the patient and the prescriber. MOPH-PDC pathway submissions are filed by the treating physician or the hospital pharmacy department, and Reserve Meds supplies the regulatory documentation package that MOPH-PDC reviewers expect.
Where the patient is followed at a non-tertiary clinic, the patient is typically referred for the Gocovri initiation visit to one of the centres above and then returns to local follow-up with monthly or quarterly tertiary review, depending on the clinical picture. Reserve Meds coordinates the refill cadence so that the next shipment is in country at least 7 days before the patient's current supply ends.
Monitoring and continuity of care
The Qatari treating physician follows a standard monitoring schedule once Gocovri is initiated:
- Unified Dyskinesia Rating Scale (UDysRS) or patient dyskinesia diary at baseline, 4 weeks, 12 weeks, and quarterly thereafter
- Renal function (serum creatinine and eGFR) at baseline and annually given renal clearance of amantadine and the need for dose adjustment as kidney function declines with age
- Orthostatic blood pressure and mental-status check at each visit because amantadine can precipitate orthostasis, hallucinations, and confusion in elderly Parkinson's patients
Reserve Meds is not involved in the clinical monitoring itself, but supplies refill cadence reminders to the patient and the treating physician so that the next-month supply is delivered in advance of the patient's next scheduled clinic visit. The first refill is shipped at week 3 of the initial cycle so that any titration adjustment from the 4-week visit can be reflected in the dose supplied for cycle 2.
Concomitant medications and safety considerations
Before Gocovri is initiated, the Qatari treating physician reconciles every concomitant prescription, over-the-counter, and herbal medicine the patient is taking. Key safety points the physician documents in the MOPH-PDC package:
- Hallucination, confusion, and frank psychosis risk is dose-related and elevated in patients with cognitive impairment, dementia with Lewy bodies overlap, or concurrent dopamine agonists; pre-existing visual hallucinations are a relative contraindication
- Suicidal ideation has been reported; the neurologist screens at baseline and at each follow-up using a validated tool (Columbia Suicide Severity Rating Scale or equivalent)
- Anticholinergic burden adds to total anticholinergic load; oxybutynin, tricyclic antidepressants, and first-generation antihistamines should be reviewed and de-prescribed where possible before initiation
The patient is given a written counselling document in the language of care identifying which symptoms warrant immediate clinical contact and which can wait for the next scheduled visit. Reserve Meds supplies a generic counselling-document template that the treating physician adapts to the patient's case.
Funding considerations in Qatar
Gocovri is supplied on a cash-pay basis. Some Qatari private medical insurers consider named-patient imports of FDA-labelled medicines on a case-by-case basis, particularly when the insurer's medical director can review the clinical rationale letter and the MOPH-PDC authorisation. Reserve Meds supplies the documentation package the insurer requires for review but does not adjudicate or process claims directly.
For self-pay patients, Reserve Meds issues a transparent quote at intake covering the drug-only band, international logistics, MOPH-PDC documentation handling, and concierge case coordination. The quote is fixed for the duration of the initial 90-day cycle and re-issued for each subsequent cycle if the dose changes. Patients are encouraged to ask their Qatari treating physician about manufacturer patient-assistance pathways where available, although most US manufacturer assistance programs are restricted to US residents.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MOH review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Qatar? Yes, when executed through the MOH named-patient framework with appropriate documentation. See our trust and compliance page.
Is Gocovri a controlled substance? No. Amantadine is not a scheduled controlled substance.
Why not use immediate-release amantadine? Immediate-release amantadine is available, but Gocovri's extended-release formulation is designed for bedtime dosing to target dyskinesia with a specific pharmacokinetic profile demonstrated in controlled trials. Your neurologist selects based on the clinical picture.
What renal dosing adjustments apply? Amantadine is renally cleared; Gocovri labeling specifies dose adjustments for reduced eGFR. Your neurologist applies the appropriate adjustment.
Will insurance cover this? Cash-pay is the default. Some Qatar private insurers consider case by case; we supply documentation but do not process claims directly.
Why not just use immediate-release amantadine which is widely available locally? Immediate-release amantadine is dosed two or three times daily and produces a flat plasma curve. Gocovri's extended-release bedtime formulation delivers peak concentrations during daytime motor activity and trough concentrations at night, an exposure profile shown in the EASE LID trials to reduce dyskinesia without worsening Parkinson's symptoms. The two products are pharmacokinetically distinct.
How quickly does Gocovri reduce dyskinesia? Most responders see measurable UDysRS improvement by week 4 to 6. The neurologist assesses response at 8 to 12 weeks before deciding to continue or discontinue.
Can the patient drive while on Gocovri? Driving is permitted once tolerability is established and the patient is free of daytime sedation, dizziness, or confusion. The neurologist documents this assessment at the 4-week visit.
What happens if the patient cannot tolerate 274 mg? The neurologist may maintain at 137 mg, which is the lower licensed dose with documented efficacy in a subset of patients. If 137 mg is also not tolerated, Gocovri is discontinued and the dyskinesia management plan is revisited.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.